Zymeworks BC Inc’s recently made public that its EVP & Chief Operating Officer Hollywood Mark unloaded Company’s shares for reported $0.14 million on Jan 12 ’26. In the deal valued at $22.67 per share,6,120 shares were sold. As a result of this transaction, Hollywood Mark now holds 132,913 shares worth roughly $3.18 million.
Then, Smith Jeffrey T L sold 9,310 shares, generating $211,090 in total proceeds. Upon selling the shares at $22.67, the EVP & Chief Medical Officer now owns 26,708 shares.
Before that, Moore Paul Andrew sold 9,560 shares. Zymeworks BC Inc shares valued at $216,759 were divested by the Chief Scientific Officer at a price of $22.67 per share. As a result of the transaction, Moore Paul Andrew now holds 48,497 shares, worth roughly $1.16 million.
Wells Fargo upgraded its Zymeworks BC Inc [ZYME] rating to an Overweight from a an Equal weight in a research note published recently. A number of analysts have revised their coverage, including Citizens JMP’s analysts, who began to cover the stock in early December with a ‘”a Mkt outperform”‘ rating. H.C. Wainwright revised its rating on October 14, 2025. It rated ZYME as “a Buy” which previously was an “a Neutral”.
Price Performance Review of ZYME
On Tuesday, Zymeworks BC Inc [NASDAQ:ZYME] saw its stock jump 3.28% to $23.92. Over the last five days, the stock has lost -1.08%. Zymeworks BC Inc shares have risen nearly 80.94% since the year began. Nevertheless, the stocks have fallen -9.15% over the past one year.
How much short interest is there in Zymeworks BC Inc?
A steep rise in short interest was recorded in Zymeworks BC Inc stocks on 2025-12-31, dropping by -2.01 million shares to a total of 3.6 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-28 was 5.61 million shares. There was a decline of -55.65%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on October 10, 2025 when B. Riley Securities began covering the stock and recommended ‘”a Buy”‘ rating along with a $30 price target.
